Clinical Trial

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Eligible participants will be randomized 1:1 to the experimental group or the control group for treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2026-06-24
Trial Details
NCT Number NCT07262567
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Metastatic Pancreatic Cancer
Enrollment 320 participants
Start Date 2025-12-04
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14